High-Efficacy Disease-Modifying Therapies for Multiple Sclerosis
December 18th 2023Jason Freeman, MD, MBA, and Abby Rogers, DMSc, PA-C, MPAS, discuss a study presented at ACTRIMS 2023 on high-efficacy disease-modifying therapies for treatment-naïve patients with multiple sclerosis. Sponsored by Novartis.
Quality of Life and Treatment Satisfaction With Disease-Modifying Therapies
October 2nd 2023Jason Freeman, MD, MBA, and Brandon Brown, PharmD, discuss the poster “Quality of Life and Treatment Satisfaction With Disease-Modifying Therapies in Multiple Sclerosis” presented at ACTRIMS 2023. Sponsored By Novartis.
How Well Do You Know COPAXONE® (glatiramer acetate injection)?
October 22nd 2021This year, Teva is celebrating the 25th anniversary of the FDA approval of COPAXONE® (glatiramer acetate injection), but the story goes back much further. Hear what some of Teva's most prominent R&D leaders have to say about the history and origins of the treatment.